Enterprise Value

2.924B

Cash

525.1M

Avg Qtr Burn

-28.81M

Short % of Float

11.30%

Insider Ownership

0.99%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Darovasertib (IDE196) (PKC Inhibitor) + crizotinib Details
Solid tumor/s, Metastatic uveal melanoma, Cancer

Phase 2/3

Update

Darovasertib Details
Solid tumor/s, Cancer, Uveal melanoma, Cutaneous Melanoma

Phase 2

Data readout

Phase 1/2

Data readout

Phase 1/2

Initiation

IDE161 Details
Cancer, Solid tumor/s, ER+/HER2- breast cancer, Ovarian cancer, Endometrial cancer

Phase 1

Data readout